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REMS: Risk Management Strategies, Current Issues,
and the Pharmacist's Role
Kristen Thatcher, sixth-year pharmacy student from Pittsburgh, Pa.; Megan Stojic, PharmD
Abstract
Risk Evaluation and Mitigation Strategies (REMS) are the most
recent risk management initiative put forth by the Food and Drug
Administration (FDA) that decreases the risk associated with
certain medications. They may be mandatory by the FDA or can
be produced voluntarily by the manufacturer in order for a drug
associated with significant risk to be approved. REMS may
include one or multiple elements, including a Medication Guide
(MedGuide), Communication Plan, Elements to Assure Safe Use
(ETASU), Implementation Plan, and Timetable for Submission
of Assessments. Although REMS enhance patient care by
reducing risk and maintaining patient safety, an unbalanced
burden is placed on the health care system to implement these
elements. A stakeholder meeting with representation from a
variety of health care provider groups was held in October 2010,
to discuss these issues and potential resolutions. Specific to the
field of pharmacy, pharmacists must be aware of REMS
requirements and how they affect medication access and patient
care in order to maintain adequate and appropriate therapy.
Introduction
Risk Evaluation and Mitigation Strategies are the newest initiative in the riskmanagement program of the Food and Drug
Administration (FDA). With the continuing development of
new drugs come new risks associated with them. Drug manufacturers present risk-benefit data to the FDA as part of the
New Drug Application (NDA), and the FDA evaluates this information during the approval process to determine necessary risk management strategies for certain products. Manufacturers may also voluntarily provide a REMS program. Additionally, new drug safety information is revealed after a
drug has been on the market and used in a larger patient
population than the small, limited population studied in clinical trials. This post-marketing data may warrant developing
or revising a REMS program. REMS programs can allow
therapeutically beneficial drugs that present significant risks
to be approved and marketed.
Risk Management History
Laws and regulations have progressed historically in order to
keep patients safe while continuing drug approvals. Risk
management strategies were first notably implemented in
the 1960s, when the FDA required manufacturers to disclose
all product information within the product labeling for health
care professionals (HCPs) to access. In the late 1970s, Patient
Package Inserts (PPis) were required to be provided to patients using oral contraceptives to explain the benefits and
risks of using the product,1.2 This was significant because
drug safety information was then being extended to patients
for them to acknowledge and be informed about risks with
their therapies. In the late 1990s, certain products such as
Accutane® (isotretinoin), Clozaril® (clozapine) and Thalomid® (thalidomide) were substantially beneficial medications for certain patient populations that also came with sigJanuary 2012 Volume 3, Issue 1

nificant risk. As a result of possible harm to the patient,
medications like these had restricted access. After some
medications were withdrawn from the market due to reported serious side effects, there was a demand for even
tighter risk management requirements. In response, the FDA
provided three guidances in 2005 for risk management initiatives-Premarketing Risk Assessment, Development and
Use of Risk Minimization Action Plans (RiskMAPs), and Good
Pharmacovigilance Practices and Pharmacoepidemiologic
Assessment.2 The RiskMAP guidance provided a direction for
manufacturers to develop a program that took necessary
actions and precautions for use of medications associated
with certain risks. This enabled a better potential for therapeutically beneficial products to become approved and remain on the market. This risk management strategy was the
precursor to the current REMS program.
The REMS Era
Similar to RiskMAPs, REMS is part of the Food and Drug Administration Amendments Act of 2007 (FDAAA) mandated
by Congress.2 This legislation replaced the former RiskMAP
risk management strategy and formalized the FDA's role in
drug development, distribution, and post-marketing commitments regarding safety issues. It also allows the FDA to enforce compliance to the program and monetarily penalize
those who do not comply.3 Depending on the specific risks of
the drug, a program may include one element or multiple
elements. Manufacturers must provide a REMS program for
the product to the FDA after notice of necessity (or voluntarily), and the program must be assessed after implementation
to determine efficacy and new safety data. The different elements that a REMS may include are listed on the following
page (Table 1). The timetable for submission of assessment
is the only mandatory part of a REMS.
REMS Example: FOCUS Program for Onsolis®s
In order to understand the complexity of a REMS program,
an example of the Onsolis® REMS will be described in more
detail. This program was chosen because it includes all REMS
elements. Onsolis® (fentanyl) is an approved opioid product
for breakthrough pain in adult cancer patients who are on
around-the-clock opioids. The buccal film dosage form dissolves when it is placed on the inside of the cheek. While the
overall goal of REMS is to mitigate risk, the specific goal of
the Full Ongoing Commitment to User Safety (FOCUS) Program for Onsolis® is to minimize the risk of overdose, abuse,
addiction, and serious complications due to medication errors. This will be accomplished by selecting the right patients, reducing exposure in individuals for whom it is not
prescribed, and training providers about proper dosing and
administration. The FOCUS Program consists of a Medication
Guide, Communication Plan, ETASU, Implementation Plan,
and Timetable for Submission of Assessments.
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Table 1. REMS Elements2,4
Medication Guide
(MedGuide)

Safety information written in patient-friendly language; must be given to patient every time
drug is dispensed

Communication Plan

Educational materials for safety and appropriate use

Elements to Assure Safe Use
(ETASU)

Strict systems or requirements to enforce the appropriate use of a drug; Examples include
the following:
• Specialized training and/or certification of health care providers
• Restricted distribution to limited settings
• Evidence or documentation of safe use conditions prior to dispensing to patient
• Registries ofprescribers, pharmacies, and/or patients
• Patient monitoring

Implementation Plan

Description of how certain ETASUs will be implemented

Timetable for Submission of
Assessments

Frequency the program must be evaluated; minimum at 18 months, 3 years, and 7 years
after the roduct is introduced to the market

Medication Guide
The Medication Guide is a six-page document.6 Before dispensing the medication for the first time, the prescriber must
counsel the patient on this document. The pharmacy staff
must also give this to the patient every time the medication is
dispensed.
Communication Plan
The Communication Plan includes a two-page6 Dear Prescriber Letter that was sent to HCPs at the time the product
was put on the market. The letter introduces the product and
provides important information about the product.
ETASU
The ETASU ensures that only certified providers and pharmacies may prescribe and dispense Onsolis®, and that the
medication is only dispensed to patients with documentation
of safe use conditions. In order to be certified, providers and
pharmacies (via the pharmacist-in-charge) are educated and
enrolled by reviewing the website or printed educational
materials and completing the appropriate enrollment forms.
The pharmacist must also review a Dear Pharmacist Letter.
Prescribers and pharmacies must be re-educated and reenrolled at least every two years or following significant
changes to the program. Pertaining specifically to pharmacy,
the pharmacy agrees to comply with several actions when
signing the enrollment form:
1. The pharmacy staff must be trained about the program and agree to provide the MedGuide every time
Onsolis® is dispensed.
2. The drug may only be dispensed after the pharmacy
confirms that the patient has a valid prescription
and has been counseled appropriately.
3. The pharmacy staff will not substitute the product.
4. The pharmacy will provide reports of Onsolis® prescription activity and allow program-related audits.
When dispensing the medication, the pharmacy must verify
that the patient and corresponding prescriber both have an
active status within the database. After this is fulfilled, the
pharmacy receives a database authorization number to allow
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the dispensing process to be completed. In addition to providers, patients are also involved in the enrollment process
and must meet safe use conditions. Each patient must be
counseled on the product and enrolled prior to receiving his/
her first prescription. The prescriber counsels the patient on
the MedGuide, the risks and benefits of the medication, and
how to appropriately use it. The patient also receives a counseling call from a FOCUS Program trained staff member. After
these steps are completed, the patient receives a unique
identification number for the database. Like prescribers and
pharmacies, patients must also re-enroll every two years or
following significant program changes.
Implementation System
The Implementation System describes the manufacturer's
responsibilities for ETASU. The manufacturer maintains and
monitors enrolled entities via the database. The manufacturer also ensures that wholesalers and distributors are specially certified (also re-enrolled every two years or following
significant program changes). The manufacturer also commits to take appropriate actions in terms of non-compliance
or if the results of the REMS program do not meet expectations.
Timetable for Submission ofAssessments
The Timetable for Submission of Assessments is set at six
months and one year after NDA approval date and annually
thereafter.

A REMS program such as this one may adequately mitigate
risk associated with the product. However, it is evident that
it affects the practices of providers, including physicians,
pharmacists, distributors, and manufacturers, as well as patients. Several issues arise from these disturbances in workflow and access.
Current Issues4,7,B
Several issues are evident with current REMS programs. Although the REMS program reduces risk, the number and
complexity of the programs required by the FDA has in-
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creased, placing an unbalanced burden on the healthcare
system. As a result, patients may not be getting the best care
possible because access to some products may be difficult
beyond the initial intent of REMS. REMS are generally burdensome and can generate administrative or staffing challenges. Providers may change prescribing habits in order to
avoid REMS requirements (i.e. prescribing a different medication without a REMS that might be less therapeutically
beneficial). Pharmacies may not supply certain products.
Adding to this difficulty, no standard compensation model
exists to make up for the extra time and resources necessary
to fulfill requirements. Additionally, a lack of a standardization and complication of programs may deter drug development, while provider time and resources are being exhausted. With a lack of standardization, different REMS requirements may be implemented for similar medications or
products with similar side effects. However, even with the
implementation of risk minimizing programs, the tools are
not as effective as they could be. Currently, MedGuides are
the most common tools used in REMS, but these tend to be
lengthy and unequally describe risks more than benefits of
the medication. Many programs are initiated without participation from providers during their development. As a result,
the program specifics are difficult to implement in primary
care, and logistics add to the complexity for providers. If
changes are warranted for an existing plan, it may take
months to approve updated programs. Also, there is currently no single resource to access all REMS information and
providers must find each program individually. All of these
issues and challenges may ultimately lead to compromised
patient care, including increased patient costs from the resultant burden on the healthcare system and higher drug costs.
Finally, as the industry is gearing toward the imminent
"patent cliff' that will shift the market even more toward
generic drugs, some brand companies may see REMS programs as a way to protect their products from generic competition. It can be challenging for generic manufacturers to
address REMS requirements in a way that is comparable to a
brand manufacturer because REMS programs can be resource intensive and margins are smaller on the generic market In addition, brand companies may use REMS programs
to restrict access to their drugs, thereby preventing generic
drug manufacturers from obtaining the drug in order to conduct bioequivalence studies required by the FDA to show
equivalent safety and effectiveness of the generic product.
This goes beyond the initial intent of REMS to mitigate
patient risk.
Stakeholder Meeting4
In October 2010, 34 stakeholders from national health care
provider associations (including physicians, physician assistants, nurses, nurse practitioners, and pharmacists), drug
manufacturer associations, community pharmacists, patient
advocates, drug distributors, and health information technology, standards, and safety organizations met to discuss the
REMS program. The FDA was also present to observe the
meeting. The discussions centered around improving REMS
by maximizing safe and effective patient medication use
while minimizing burden on the healthcare system. SuggesJanuary 2012 Volume 3, Issue 1
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tions to accomplish this included the following: using effective risk management tools and interventions, having a standardized REMS program, allowing easy and neutral implementation of REMS programs, and outlining a model for
proper compensation. The stakeholders discussed these issues and proposed solutions to improve the REMS system.
One of the first areas targeted was the use of effective risk
management tools. In terms of effectiveness, direct patient
intervention such as medication therapy management
(MTM) was regarded as one of the most effective means for
communicating with patients about potential risks and benefits of therapy and already includes REMS-required components in its framework. MTM is a personal consultation with
a patient to ensure proper therapy, including pharmacologic
and non-pharmacologic interventions. This patient-centered
program allows healthcare providers to communicate with
patients in order to identify problems with therapy, monitor
the disease state and outcomes, follow-up with other professionals, and provide time for important education and counseling. MTM tailors therapy around the patient and REMS
could effectively be integrated into this intervention. Ideas
were also put forth to combine MedGuides, consumer medication info, and patient package inserts into one easy to read
document called patient medication information, which
could be discussed during an MTM.
Additionally, REMS programs, particularly those with
ETASUs, need to include more input from providers during
development This could be accomplished by conducting pilot test REMS programs prior to implementation. With this,
the program must also be flexible in order to reevaluate and
adapt appropriately with post-marketing safety data. Standardized processes would permit more concise provider responsibilities. Drugs in similar classes or with similar risks
would be managed in a comparable manner.
Another important improvement stakeholders discussed was
the ease of implementation into current workspace. REMS
execution should be incorporated using existing technology
and be integrated smoothly into workflow. An electronic resource or clearinghouse for all REMS information would simplify the process and allow easy access to pertinent information. Providers may also use a unique identifier, such as a
National Provider Identifier (NPI), to track specific requirements needed to prescribe and dispense products requiring
REMS. Offering stakeholders the opportunity to fulfill continuing education requirements with REMS specialized training would serve as an incentive for completion.
Lastly, many complications exist in developing a compensation model. All stakeholders agreed that this issue must be
addressed appropriately for the future.
Pharmacist's Role
Pharmacy practice is affected by the implementation of
REMS. At the stakeholder meeting, pharmacists were acknowledged for their importance in these risk management
programs. Pharmacists can be up to date on all of the REMS
requirements and can coordinate implementation activities
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and responsibilities with other providers. As the drug experts, it is important for pharmacists to be aware and understand what requirements physicians must comply with for
specific REMS. Recently, to address the lack of standardization issue, the FDA is requiring the creation of class-wide
REMS programs for certain product families.a In demonstrating this, the large scaled long-acting and extended-release
opioids REMS program will soon be effective as part of a plan
to reduce prescription drug abuse. Pharmacists should be
aware of what this program includes and how it ·will affect
their patients. In the hospital setting, pharmacists who serve
on the Pharmacy and Therapeutics (P&T) Committee must
know REMS components and understand how it affects formulary inclusion for their hospital. Protocols, liability, finances, and outcomes are all important issues to address. 9.10
Pharmacists will also have the opportunity to be integral
players in MTM services for patients if these services are incorporated into the REMS framework, providing patientcentered care and tailoring REMS safety issues to their therapies. With the increasing number of REMS and prospects of
an increased role of the pharmacist in MTM consultations,
pharmacists and professional organizations must continue to
advocate for MTM legislation, including a standard reimbursement model for these services. Advocacy for a REMS
compensation model must also be addressed.

2010 Jun;30(6 Pt 2):35S-41S.
10. Raber JH. The formulary process from a risk management perspective.
Pharmacotherapy. 2010 Jun;30(6 Pt 2):42S-7S.

Conclusion
Risk management has evolved to include REMS programs
designed to prevent or minimize serious adverse events
when using certain medications. The inclusion of REMS affects the pharmaceutical industry, health care providers, and
patients. The current REMS model brings several concerns,
and different stakeholders, organizations, and the FDA are
looking to improve this system in the next few years. Pharmacists will continue to play an integral role in patient care,
and have to remain aware and active when it comes to implementing REMS programs. Overall, REMS programs and associated drug safety efforts from all health care stakeholders
should continue to advance patient education, safety, and
quality of care.
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